Simplex Trading’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-88,400
| Closed | -$1.9M | – | 9476 |
|
|
2026
Q1 | $1.9M | Buy |
+88,400
| New | +$1.25M | ﹤0.01% | 1864 |
|
|
2025
Q4 | – | Sell |
-200
| Closed | -$1K | – | 8847 |
|
|
2025
Q3 | $1K | Buy |
+200
| New | +$1.38K | ﹤0.01% | 8788 |
|
|
2025
Q2 | – | Sell |
-3,200
| Closed | -$25K | – | 8835 |
|
|
2025
Q1 | $25K | Sell |
3,200
-7,800
| -71% | -$84K | ﹤0.01% | 6393 |
|
|
2024
Q4 | $139K | Sell |
11,000
-40,200
| -79% | -$559K | ﹤0.01% | 4873 |
|
|
2024
Q3 | $713K | Sell |
51,200
-1,100
| -2% | -$15.7K | ﹤0.01% | 3237 |
|
|
2024
Q2 | $720K | Buy |
52,300
+39,800
| +318% | +$582K | ﹤0.01% | 3263 |
|
|
2024
Q1 | $206K | Buy |
12,500
+10,500
| +525% | +$157K | ﹤0.01% | 4821 |
|
|
2023
Q4 | $29K | Sell |
2,000
-300
| -13% | -$3.64K | ﹤0.01% | 6582 |
|
|
2023
Q3 | $28K | Sell |
2,300
-1,200
| -34% | -$15.7K | ﹤0.01% | 6306 |
|
|
2023
Q2 | $41K | Buy |
3,500
+2,800
| +400% | +$36.6K | ﹤0.01% | 6033 |
|
|
2023
Q1 | $9K | Buy |
700
+200
| +40% | +$3.91K | ﹤0.01% | 7607 |
|
|
2022
Q4 | $10K | Sell |
500
-700
| -58% | -$14.4K | ﹤0.01% | 7524 |
|
|
2022
Q3 | $24K | Sell |
1,200
-45,400
| -97% | -$966K | ﹤0.01% | 7317 |
|
|
2022
Q2 | $834K | Buy |
+46,600
| New | +$481K | ﹤0.01% | 2823 |
|
Other funds holding DAWN
Simplex Trading's DAWN Position: Q2 2026 in Review
Simplex Trading sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 64,464 shares — an estimated $1.38M sold.
Simplex Trading first reported a position in DAWN in Q2 2022 and held it in 8 quarters. The position peaked at $2.38M in Q2 2022. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Simplex Trading reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Simplex Trading sold 64,464 Day One Biopharmaceuticals shares in Q2 2026, an estimated $1.38M.
- Simplex Trading first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 8 quarters.
- Simplex Trading's Day One Biopharmaceuticals position peaked at $2.38M in Q2 2022.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.